Logo 25 mg Pill - yellow capsule/oblong, 13mm
Pill with imprint Logo 25 mg is Yellow, Capsule/Oblong and has been identified as Cyclosporine 25 mg. It is supplied by Teva Pharmaceuticals USA.
Cyclosporine is used in the treatment of Organ Transplant, Rejection Prophylaxis; Rheumatoid Arthritis; Psoriasis and belongs to the drug class calcineurin inhibitors. Risk cannot be ruled out during pregnancy. Cyclosporine 25 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for Logo 25 mg
Cyclosporine
- Imprint
- Logo 25 mg
- Strength
- 25 mg
- Color
- Yellow
- Size
- 13.00 mm
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Calcineurin inhibitors
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Teva Pharmaceuticals USA
- Inactive Ingredients
-
alcohol,
alpha-tocopherol,
FD&C Blue No. 2,
aluminum oxide,
gelatin,
glycine,
glycerin,
polyoxyl 40 hydrogenated castor oil,
polyglyceryl-3 oleate,
polyglyceryl-10 oleate,
propylene glycol,
shellac,
sorbitol,
titanium dioxide,
ferric oxide yellow
Note: Inactive ingredients may vary.
Labelers / Repackagers
| NDC Code | Labeler / Repackager |
|---|---|
| 00172-7310 (Discontinued) | Ivax Pharmaceuticals, Inc. |
| 00093-5740 (Discontinued) | Teva Pharmaceuticals USA, Inc. |
Related images for "Logo 25 mg"
More about cyclosporine
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (22)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: calcineurin inhibitors
- Breastfeeding
- En español
Patient resources
- Cyclosporine oral/injection drug information
- Cyclosporine (Intravenous) (Advanced Reading)
- Cyclosporine (Oral) (Advanced Reading)
- Cyclosporine Capsules, Modified
- Cyclosporine Injection
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
